Avidity Biosciences, Inc. (RNA) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Avidity Biosciences, Inc. (RNA) Bundle
Discover the true potential of Avidity Biosciences, Inc. (RNA) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how modifications influence Avidity Biosciences, Inc. (RNA) valuation – all within one comprehensive Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.3 | 6.8 | 9.3 | 9.2 | 9.6 | 12.9 | 17.4 | 23.5 | 31.7 | 42.9 |
| Revenue Growth, % | 0 | 192.67 | 37.41 | -1.09 | 3.64 | 34.99 | 34.99 | 34.99 | 34.99 | 34.99 |
| EBITDA | -16.8 | -43.8 | -117.4 | -177.5 | -233.5 | -12.9 | -17.4 | -23.5 | -31.7 | -42.9 |
| EBITDA, % | -722.29 | -644.95 | -1258.97 | -1924.61 | -2442.44 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .6 | .4 | .6 | 1.4 | 2.1 | 1.9 | 2.6 | 3.5 | 4.8 | 6.4 |
| Depreciation, % | 25.74 | 5.5 | 6.85 | 15.04 | 21.98 | 15.02 | 15.02 | 15.02 | 15.02 | 15.02 |
| EBIT | -17.3 | -44.1 | -118.1 | -178.9 | -235.6 | -12.9 | -17.4 | -23.5 | -31.7 | -42.9 |
| EBIT, % | -748.04 | -650.45 | -1265.83 | -1939.65 | -2464.41 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 94.6 | 328.1 | 405.5 | 610.7 | 595.4 | 12.9 | 17.4 | 23.5 | 31.7 | 42.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1.2 | .9 | .0 | 1.1 | 1.0 | 1.4 | 1.8 | 2.5 | 3.3 |
| Account Receivables, % | 0 | 17.68 | 9.65 | 0 | 11.56 | 7.78 | 7.78 | 7.78 | 7.78 | 7.78 |
| Inventories | .0 | -1.2 | -.9 | .0 | .0 | -.7 | -1.0 | -1.3 | -1.7 | -2.3 |
| Inventories, % | 0.000043122035 | -17.68 | -9.65 | 0.000010841284 | 0 | -5.47 | -5.47 | -5.47 | -5.47 | -5.47 |
| Accounts Payable | 2.3 | 7.7 | 2.8 | 4.6 | 8.8 | 9.6 | 13.0 | 17.5 | 23.6 | 31.9 |
| Accounts Payable, % | 99.53 | 114.12 | 30.09 | 50.27 | 92.14 | 74.41 | 74.41 | 74.41 | 74.41 | 74.41 |
| Capital Expenditure | -.2 | -1.1 | -3.7 | -2.8 | -4.2 | -3.6 | -4.9 | -6.6 | -9.0 | -12.1 |
| Capital Expenditure, % | -10.13 | -16.09 | -40.1 | -30.6 | -44.23 | -28.23 | -28.23 | -28.23 | -28.23 | -28.23 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -22.5 | -43.8 | -117.4 | -173.9 | -235.6 | -12.8 | -17.3 | -23.3 | -31.5 | -42.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.9 | -39.1 | -125.5 | -173.5 | -234.7 | -12.9 | -16.3 | -22.0 | -29.7 | -40.1 |
| WACC, % | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -90.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -41 | |||||||||
| Terminal Value | -610 | |||||||||
| Present Terminal Value | -401 | |||||||||
| Enterprise Value | -492 | |||||||||
| Net Debt | -175 | |||||||||
| Equity Value | -317 | |||||||||
| Diluted Shares Outstanding, MM | 73 | |||||||||
| Equity Value Per Share | -4.34 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real Avidity Biosciences (RNA) financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Avidity Biosciences' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as target market size, R&D expenses, and clinical trial timelines.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and other financial indicators.
- High-Precision Accuracy: Leverages Avidity Biosciences' (RNA) actual financial data for dependable valuation results.
- Simplified Scenario Testing: Easily evaluate various hypotheses and analyze different outcomes.
- Efficiency Booster: Streamlines the process, removing the need for intricate valuation models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template with Avidity Biosciences, Inc.'s (RNA) data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Avidity Biosciences, Inc.'s (RNA) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose Avidity Biosciences, Inc. (RNA)?
- Innovative Solutions: Cutting-edge RNA-targeted therapies designed to address unmet medical needs.
- Proven Expertise: A team of industry veterans dedicated to advancing RNA science and technology.
- Robust Pipeline: A diverse portfolio of candidates in various stages of development for multiple indications.
- Commitment to Quality: Adherence to rigorous standards ensures the highest level of safety and efficacy.
- Collaborative Approach: Partnerships with leading organizations to enhance research and development efforts.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for assessing Avidity Biosciences, Inc. (RNA) stock.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights and recommendations for clients interested in Avidity Biosciences, Inc. (RNA).
- Students and Educators: Utilize real-time data to enhance learning and practice in financial modeling within the biotech industry.
- Healthcare Analysts: Gain insights into how innovative biotech companies like Avidity Biosciences, Inc. (RNA) are valued in the market.
What the Template Contains
- Pre-Filled Data: Includes Avidity Biosciences, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Avidity Biosciences, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.